- Invokana, a sodium glucose co-transporter 2 (SGLT2) inhibitor, was approved as a standalone drug in March 2013.
- Invokamet is the first FDA-approved fixed-dose combination of an SGLT2 inhibitor with metformin.
- Phase III studies showed that treatment with Invokamet more effectively lowers blood sugar, reduces body weight, and decreases blood sugar than metformin alone.
Since its launch, Invokana has become the number one newly prescribed, non-insulin medication for the treatment of type 2 diabetes. In roughly 17 months, endocrinologists have written about one million prescriptions for the drug.
Invokamet facilitates customized dosing schedules. Therefore, many experts think that this new product may help mollify the pill burden for patients with type 2 diabetes.